Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
Eur Heart J Cardiovasc Pharmacother. 2022; online ahead of print DOI: 10.1093/ehjcvp/pvac054
Previously, finerenone has demonstrated CV and kidney benefits in patients with T2D and CKD in the FIDELIO-DKD and FIGARO-DKD trials. Almost 50% of patients in the pooled database of these trials, the FIDELITY database, had a history of ASCVD. As patients with ASCVD are at greater risk for HF, the present analysis investigated whether the cardiorenal benefits of finerenone were consistent, irrespective of comorbid ASCVD.
The incidence of the composite CV outcome (CV death, non-fatal MI, non-fatal stroke or HHF) and all-cause mortality were higher in patients with ASCVD versus those without. However, finerenone consistently reduced outcomes versus placebo in patients with and without ASCVD. AEs were consistent between treatment arms across ASCVD subgroups.